Zealand Pharma AS (OCSE:ZEAL, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $54.77 million, and the earnings are expected to come in at -$4.06 per share. The full year 2024's revenue is expected to be $163.56 million and the earnings are expected to be -$13.88 per share. More detailed estimate data can be found on the Forecast page.
Zealand Pharma AS (OCSE:ZEAL, Financial) Estimates Trends
Revenue estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from $190.56 million to $163.57 million for the full year 2024 and from $0.83 billion to $0.73 billion for 2025 over the past 90 days. Earnings estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from -$10.59 per share to -$13.88 per share for the full year 2024 and from -$10.36 per share to -$14.53 per share for 2025 over the past 90 days.
Zealand Pharma AS (OCSE:ZEAL, Financial) Reported History
In the previous quarter of June 30, 2024, Zealand Pharma AS's (OCSE:ZEAL) actual revenue was $34.13 million, which beat analysts' revenue expectations of $12.79 million by 166.9%. Zealand Pharma AS's (OCSE:ZEAL) actual earnings were -$4.67 per share, which missed analysts' earnings expectations of -$4.21 per share by -10.85%. After releasing the results, Zealand Pharma AS (OCSE:ZEAL) was up by 3.19% in one day.
Zealand Pharma AS (OCSE:ZEAL, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 10 analysts, the average target price for Zealand Pharma AS (OCSE:ZEAL) is $1,003.10 with a high estimate of $1,106 and a low estimate of $800. The average target implies an upside of 21.29% from the current price of $827.
Based on GuruFocus estimates, the estimated GF Value for Zealand Pharma AS (OCSE:ZEAL, Financial) in one year is $0, suggesting a downside of -100% from the current price of $827.
Based on the consensus recommendation from 11 brokerage firms, Zealand Pharma AS's (OCSE:ZEAL, Financial) average brokerage recommendation is currently 2.1, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
